MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma

BackgroundThe enhancer of zeste homolog 2 (EZH2) was found to be overexpressed and associated with tumor metastasis in esophageal squamous cell carcinoma (ESCC). On the other hand, it was reported that miR-26a, miR-98, miR-101, miR-124, miR-138 and miR-214 could inhibit the expression of EZH2 in some tumors. However, the role of miRNAs in the regulation of EZH2 expression in human ESCC has not been documented. The aim of this study was to determine the role of these miRNAs in the regulation of tumor metastasis via EZH2 overexpression in human ESCC.Methods and resultsThe expression of these miRNAs and EZH2 mRNA were examined by qPCR and the expression of EZH2 protein was detected by western blot. The role of these miRNAs in migration and invasion was studied in ESCC cell line (Eca109) transfected with miRNA mimics or cotransfected with miRNA mimics and pcDNA-EZH2 plasmid (without the 3’-UTR of EZH2). Through clinical investigation, we found that miR-98 and miR-214 expression was significantly lower in ESCC tissues than in matched normal tissues, and the expression level of miR-98 and miR-214 was inversely correlated to EZH2 protein expression and the clinical features such as pathological grade, tumor stage and lymph node metastasis in ESCC. In Eca109 cells, overexpression of miR-98 and miR-214 significantly inhibited the migration and invasion of ESCC cells, which was reversed by transfection of EZH2.ConclusionsThese findings suggest that decreased expression of miR-98 and miR-214 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein.

[1]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[2]  J. Gaughan,et al.  Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16INK4A, p27KIP1, p21WAF1, Ki‐67 expression patterns in gastric cancer , 2007, Journal of cellular physiology.

[3]  Lan-Jun Zhang,et al.  High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy , 2010, International journal of cancer.

[4]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[5]  Ying Chen,et al.  MiR-26 a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH 2 , 2010 .

[6]  F. Crea,et al.  An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Osaki,et al.  High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. , 2009, Oral oncology.

[8]  N. Meiri,et al.  MiR‐138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition , 2011, The European journal of neuroscience.

[9]  Cheng-Ping Yu,et al.  Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus , 2009, Modern Pathology.

[10]  B. H. Haug,et al.  Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma , 2011, British Journal of Cancer.

[11]  Jun Yu,et al.  Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma , 2007, Proteomics.

[12]  Fang Wang,et al.  Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. , 2006, Biochemical and biophysical research communications.

[13]  J Alfred Witjes,et al.  Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. , 2007, European urology.

[14]  Hua Zhang,et al.  Dysregulation of miR-15a and miR-214 in human pancreatic cancer , 2010, Journal of hematology & oncology.

[15]  Kun Li,et al.  Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients , 2009, Clinical & Experimental Metastasis.

[16]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Andrew Feber,et al.  MicroRNA expression profiles of esophageal cancer. , 2008, The Journal of thoracic and cardiovascular surgery.

[18]  P. Enzinger,et al.  Esophageal cancer. , 2003, The New England journal of medicine.

[19]  V. Rotter,et al.  Activated p53 suppresses the histone methyltransferase EZH2 gene , 2004, Oncogene.

[20]  N. Rajewsky,et al.  The evolution of gene regulation by transcription factors and microRNAs , 2007, Nature Reviews Genetics.

[21]  N. Palanisamy,et al.  Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. , 2011, Carcinogenesis.

[22]  Kai-lai Sun,et al.  Gene expression patterns in gastric cancer. , 2006, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[23]  T. Utsunomiya,et al.  Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.

[24]  C. Harris,et al.  RESEARCH ARTICLE Open Access Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study , 2022 .

[25]  Lu Wang,et al.  MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. , 2011, Cancer research.

[26]  X. Bian,et al.  The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2 , 2011, Gut.

[27]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[28]  Xin Li,et al.  MicroRNA‐214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells , 2009, IUBMB life.

[29]  M. Krasna,et al.  Multimodality treatment of esophageal cancer. , 2005, The Surgical clinics of North America.

[30]  Ming Lei,et al.  Researchnegatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β , 2010 .

[31]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Slack,et al.  The let-7 family of microRNAs. , 2008, Trends in cell biology.

[33]  Stephen A Boorjian,et al.  Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.

[34]  A. Hui,et al.  Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98 , 2010, Cell Death and Disease.

[35]  E. Spisni,et al.  MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. , 2009, Experimental cell research.

[36]  J. Luk,et al.  Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas , 2005, Clinical Cancer Research.

[37]  A. S. Cheng,et al.  Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2 , 2011, Journal of gastroenterology and hepatology.

[38]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.